China Pharma Holdings, Inc.
Here’s whether China Pharma Holdings, Inc. (CPHI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+36.45% over 10 days); RSI 53 — healthy momentum range; 3-month momentum positive (+141.5%); rising volume confirms the move (2.62x 30d avg). Concerns: weak 1-year return of -16.2%. Currently 92.1% off its 52-week high. Score: +6/7.
CPHI is in a confirmed uptrend, trading above both its 50-day ($0.98) and 200-day ($1.08) moving averages. An RSI of 52.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -16.3% compares to +16.5% for SPY (trailed the market by 32.7%). The current 92.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.